Segall Bryant & Hamill LLC Takes Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Segall Bryant & Hamill LLC bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 18,968 shares of the company’s stock, valued at approximately $921,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. TD Asset Management Inc lifted its stake in shares of Amphastar Pharmaceuticals by 67.4% in the 2nd quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock valued at $67,663,000 after acquiring an additional 680,976 shares during the last quarter. Epoch Investment Partners Inc. raised its position in Amphastar Pharmaceuticals by 35.1% during the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock valued at $43,154,000 after purchasing an additional 280,390 shares during the last quarter. American Century Companies Inc. raised its position in Amphastar Pharmaceuticals by 19.7% during the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock valued at $29,616,000 after purchasing an additional 121,764 shares during the last quarter. Millennium Management LLC raised its position in Amphastar Pharmaceuticals by 84.6% during the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock valued at $29,550,000 after purchasing an additional 338,653 shares during the last quarter. Finally, Boston Trust Walden Corp bought a new position in Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $26,189,000. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Up 2.0 %

AMPH stock opened at $45.46 on Friday. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The business’s 50 day moving average price is $48.26 and its two-hundred day moving average price is $44.44. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of 15.15, a price-to-earnings-growth ratio of 0.89 and a beta of 0.82.

Analyst Upgrades and Downgrades

AMPH has been the subject of a number of recent analyst reports. Wells Fargo & Company initiated coverage on Amphastar Pharmaceuticals in a research report on Friday. They set an “equal weight” rating and a $55.00 price target for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Finally, StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $60.33.

Insiders Place Their Bets

In related news, EVP Yakob Liawatidewi sold 5,214 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $271,388.70. Following the sale, the executive vice president now owns 74,938 shares in the company, valued at $3,900,522.90. This represents a 6.51 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO William J. Peters sold 7,426 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $386,523.30. Following the completion of the sale, the chief financial officer now owns 94,103 shares in the company, valued at $4,898,061.15. The trade was a 7.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 31,533 shares of company stock worth $1,571,652. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.